NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Peter Michael Ellis; Geoffrey Liu; Michael Millward; Francesco Perrone; Frances A. Shepherd; Sophie Sun; Byoung Chul Cho; Alessandro Morabito; Martin R. Stockler; Rafal Wierzbicki; Victor Cohen; Normand Blais; Randeep S. Sangha; Adolfo G. Favaretto; Jin Hyoung Kang; Carolyn F. Wilson; Joseph O'Connell; Keyue Ding; Glenwood D. Goss; Penelope Ann Bradbury

doi:10.1200/jco.2014.32.15_suppl.8036

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8036 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8036-8036 ◽

Cited By ~ 6

Author(s):

Peter Michael Ellis ◽

Geoffrey Liu ◽

Michael Millward ◽

Francesco Perrone ◽

Frances A. Shepherd ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Prior Chemotherapy ◽

Egfr Tki

Download Full-text

C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283190.70038.e9 ◽

2007 ◽

Vol 2 (8) ◽

pp. S359 ◽

Cited By ~ 3

Author(s):

Siow-Ming Lee ◽

Penella J. Woll ◽

Robin M. Rudd ◽

Nicole H. Gower ◽

Christian H. Ottensmeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase III randomised, double blind, placebo controlled trial of carboplatin/etoposide with or without thalidomide in small cell lung cancer

http://isrctn.org/> ◽

10.1186/isrctn16174527 ◽

2013 ◽

Author(s):

Siow Ming Lee

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase III randomized double blind placebo controlled trial of cisplatin(P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung cancer (SCLC)

Lung Cancer ◽

10.1016/0169-5002(94)94116-5 ◽

1994 ◽

Vol 11 ◽

pp. 90 ◽

Cited By ~ 1

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text

PRS-04: A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283089.56099.79 ◽

2007 ◽

Vol 2 (8) ◽

pp. S306-S307 ◽

Cited By ~ 14

Author(s):

Siow-Ming Lee ◽

Penella J. Woll ◽

Lindsay E. James ◽

Matthew Hatton ◽

Kulsam Ali ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090830.544164 ◽

2007 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Extensive Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Response To Chemotherapy

Download Full-text

A phase II/III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced Non-Small Cell Lung Cancer (NSCLC)

http://isrctn.org/> ◽

10.1186/isrctn77341241 ◽

2012 ◽

Author(s):

Siow Ming Lee

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2021.09.010 ◽

2021 ◽

Author(s):

John V. Heymach ◽

Tetsuya Mitsudomi ◽

David Harpole ◽

Mike Aperghis ◽

Stephanie Jones ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

SpringerPlus ◽

10.1186/s40064-015-1067-7 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 8

Author(s):

Constantin Volovat ◽

Igor M Bondarenko ◽

Oleg A Gladkov ◽

Reiner Elsässer ◽

Anton Buchner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7631 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7631-7631 ◽

Cited By ~ 11

Author(s):

M. Schuster ◽

J. R. Rigas ◽

S. V. Orlov ◽

B. Milovanovic ◽

K. Prabhash ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)

A phase III randomised, double blind, placebo controlled trial of carboplatin/etoposide with or without thalidomide in small cell lung cancer

Phase III randomized double blind placebo controlled trial of cisplatin(P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung cancer (SCLC)

PRS-04: A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC)

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Faculty Opinions recommendation of Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

A phase II/III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced Non-Small Cell Lung Cancer (NSCLC)

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial